Analyst firms · BTIG · RCEL
BTIG RCEL price target and rating history
Avita Medical Inc. (RCEL) · Health Care
BTIG rates Avita Medical Inc. (RCEL) Buy with a $7 price target, as of its latest action on Aug 7, 2026. It has published 4 rating actions on RCEL since April 2024, including 2 upgrades and 2 downgrades. Across 3 firms with a RCEL price target in the last 12 months, the median target is $7. BTIG's target matches it.
- Current rating
- Buy
- Price target
- $7
- Median target, all firms
- $7
- Actions on RCEL
- 4
BTIG price target on RCEL
Every BTIG rating on RCEL
- Aug 7, 2026
- Nov 20, 2025
- Aug 8, 2025
- Apr 11, 2024DowngradeBTIG downgrades to Neutral from Buy
How other firms rate RCEL
Each firm's latest rating and stated target in the last 12 months.
| Firm | Rating | Price target | Date |
|---|---|---|---|
| BTIG | Buy | $7 | Aug 7, 2026 |
| Lake Street | Buy | $6 | May 15, 2026 |
| Northland Capital Markets | Outperform | $10 | Mar 5, 2026 |
Questions about BTIG and RCEL
- What is BTIG's price target for RCEL?
- BTIG's latest stated price target for Avita Medical Inc. (RCEL) is $7, from its action on Aug 7, 2026.
- What is BTIG's rating on RCEL?
- BTIG rates RCEL Buy, a bullish rating, as of Aug 7, 2026.
- When did BTIG last change its view on RCEL?
- On Aug 7, 2026, BTIG upgrades to Buy from Neutral, price target $7.
- How does BTIG's RCEL target compare with other analysts?
- Across 3 firms with a RCEL price target in the last 12 months, the median target is $7. BTIG's target matches it.
All BTIG ratingsRCEL news and filingsEvery analyst firm
From rating actions in the Quantisnow feed. A target holds until the firm states a new one; a reiteration with no target keeps the last one. Not investment advice.